Acurx Pharmaceuticals Inc (ACXP) Stock Price, Quote & News

Company Profile

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant st...

Industry: Biotechnology

Sector: Healthcare

Phone: 917 533 1469

Website: www.acurxpharma.com

Address:

259 Liberty Avenue, Staten Island, United States

Bonso99 Aug. 18 at 12:25 PM

$ACXP 🫡🫡🫡🫡🫡🫡

0 · Reply

Bonso99 Aug. 15 at 7:25 PM

$ACXP @MS_Tammy look at this one 🫡

0 · Reply

Bonso99 Aug. 15 at 7:21 PM

$ACXP @topstockalerts watch this one 🫡

0 · Reply

makedatbread88 Aug. 15 at 7:07 PM

$ACXP 1.54M float recent reverse split volume starting to come in low float 1 week chart looking good too keep an eye on it!

0 · Reply

Bulltrader988 Aug. 15 at 6:22 PM

$ACXP 👃👀

1 · Reply

knonaogn Aug. 15 at 6:07 PM

$ACXP This stock preparation for the rise I advise starting investing here $1,000

0 · Reply

knonaogn Aug. 15 at 6:00 PM

$ACXP This stock, if successful It doesn't stop at $100.

1 · Reply

Bonso99 Aug. 15 at 5:54 PM

$ACXP getting geared up🫡🫡🫡🫡 Next week is going to be epic 🚀🚀🚀🚀

2 · Reply

knonaogn Aug. 15 at 5:35 PM

$ACXP will soon explode this very good stock I advise to invest. Inside.

0 · Reply

cninc Aug. 15 at 5:08 PM

$ACXP with Armistice here you are always just a HFT pump away.

5 · Reply

Acurx Pharmaceuticals, Inc. (ACXP) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 7:01 AM EDT - 6 days ago

Acurx Pharmaceuticals, Inc. Reports Second Quarter Results and Provides Business Update

Jul 31, 2025, 9:25 AM EDT - 18 days ago

Acurx Pharmaceuticals, Inc. Announces Reverse Stock Split

Jul 24, 2025, 7:01 AM EDT - 25 days ago

Acurx Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 12, 2025 Conference Call and Provide Business Update

Jun 17, 2025, 9:47 PM EDT - 2 months ago

Acurx Pharmaceuticals, Inc. Announces Exercise of Warrants for $2.67 Million Gross Proceeds

Jun 17, 2025, 7:01 AM EDT - 2 months ago

Acurx Announces Publication in Lancet Microbe of Phase 2b Clinical Trial Data for Ibezapolstat in CDI

Jun 9, 2025, 7:30 AM EDT - 2 months ago

Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Federation of American Societies for Experimental Biology Scientific Conference

May 13, 2025, 1:59 PM EDT - 3 months ago

Acurx Pharmaceuticals, Inc. (ACXP) Q1 2025 Earnings Call Transcript

May 13, 2025, 7:01 AM EDT - 3 months ago

Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update

Apr 30, 2025, 7:30 AM EDT - 3 months ago

Acurx Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 13, 2025 Conference Call and Provide Business Update

Apr 28, 2025, 7:30 AM EDT - 4 months ago

Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase

Apr 17, 2025, 7:30 AM EDT - 4 months ago

Indian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors

Mar 18, 2025, 9:44 AM EDT - 5 months ago

Acurx Pharmaceuticals, Inc. (ACXP) Q4 2024 Earnings Call Transcript

Mar 18, 2025, 7:01 AM EDT - 5 months ago

Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Mar 10, 2025, 4:30 PM EDT - 5 months ago

Acurx Pharmaceuticals, Inc. Announces Closing of $1.1 Million Registered Direct Offering

Mar 7, 2025, 8:00 AM EST - 5 months ago

Acurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct Offering

Mar 3, 2025, 8:00 AM EST - 6 months ago

Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics

Feb 28, 2025, 8:00 AM EST - 6 months ago

Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on March 18, 2025 Conference Call and Provide Business Update

Feb 24, 2025, 8:00 AM EST - 6 months ago

Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI

Feb 19, 2025, 8:00 AM EST - 6 months ago

JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors

Jan 7, 2025, 5:00 PM EST - 7 months ago

Acurx Pharmaceuticals, Inc. Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 6, 2025, 5:35 PM EST - 7 months ago

Acurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 6, 2025, 8:30 AM EST - 8 months ago

Acurx Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI)

Dec 11, 2024, 11:00 AM EST - 8 months ago

Acurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025 - January 30, 2025

Dec 9, 2024, 8:00 AM EST - 9 months ago

Acurx Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA Communications

Nov 20, 2024, 10:53 AM EST - 9 months ago

Acurx Pharmaceuticals to add up to $1 million in bitcoin for treasury reserve, following MicroStrategy's playbook

Nov 20, 2024, 7:01 AM EST - 9 months ago

Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset

Nov 18, 2024, 7:00 AM EST - 9 months ago

Acurx Sponsored and Participated in the Peggy Lillis Foundation Inaugural CDI Scientific Symposium and Presented Ibezapolstat Ph2b Clinical Data Update

Nov 13, 2024, 11:43 AM EST - 9 months ago

Acurx Pharmaceuticals, Inc. (ACXP) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 7:00 AM EST - 9 months ago

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update

Oct 21, 2024, 10:07 AM EDT - 10 months ago

Acurx Ready To Expand Pipeline With Anthrax Treatment

Oct 21, 2024, 7:00 AM EDT - 10 months ago

Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific Conference

Oct 17, 2024, 8:00 AM EDT - 10 months ago

Acurx Pharmaceuticals Announces Participation at The Spartan Capital Investor Conference to Showcase Growth Companies and Foster High-Level Investor Engagement

Oct 16, 2024, 8:00 AM EDT - 10 months ago

Acurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024

Oct 14, 2024, 1:00 PM EDT - 11 months ago

New to the Street Resigns Acurx Pharmaceuticals, Inc. to Multi-Platform Media Series Featuring Broadcast Television, Earned Media, and Outdoor Advertising Support

Oct 11, 2024, 10:50 AM EDT - 11 months ago

New to the Street Announces Exclusive Bloomberg Lineup for October 11 at 6:30 PM EST

Sep 26, 2024, 7:00 AM EDT - 11 months ago

Acurx Announces Additional Ibezapolstat Ph2b Results in CDI as well as Anthrax (B. anthracis) Susceptibility to ACX-375 Analogues

Sep 24, 2024, 7:00 AM EDT - 11 months ago

Acurx Announces Results of Its Pioneering Research with Ibezapolstat in Collaboration with Leiden University Medical Center at the Premier International C. difficile Symposium

Aug 26, 2024, 7:00 AM EDT - 1 year ago

ACURX PHARMACEUTICALS ANNOUNCES PARTICIPATION AT THE H.C. Wainwright 26th Annual Global Investment Conference

Aug 9, 2024, 10:20 AM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. (ACXP) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 7:01 AM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2024 Results and Provides Business Update

Jul 17, 2024, 7:00 AM EDT - 1 year ago

USPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome

Jul 16, 2024, 7:00 AM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. to Discuss Second Quarter 2024 Financial Results on August 9, 2024 Conference Call and Provide Business Update

Jul 15, 2024, 7:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific Conference

May 15, 2024, 1:14 PM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. (ACXP) Q1 2024 Earnings Call Transcript

May 15, 2024, 9:00 AM EDT - 1 year ago

Acurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile Infection

May 15, 2024, 7:00 AM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update

May 2, 2024, 7:00 AM EDT - 1 year ago

Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference

Apr 25, 2024, 10:12 AM EDT - 1 year ago

Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific Conference

Apr 23, 2024, 10:57 AM EDT - 1 year ago

Acurx Pharmaceuticals, Inc. to Discuss First Quarter 2024 Financial Results on May 15, 2024 Conference Call and Provide Business Update

Bonso99 Aug. 18 at 12:25 PM

$ACXP 🫡🫡🫡🫡🫡🫡

0 · Reply

Bonso99 Aug. 15 at 7:25 PM

$ACXP @MS_Tammy look at this one 🫡

0 · Reply

Bonso99 Aug. 15 at 7:21 PM

$ACXP @topstockalerts watch this one 🫡

0 · Reply

makedatbread88 Aug. 15 at 7:07 PM

$ACXP 1.54M float recent reverse split volume starting to come in low float 1 week chart looking good too keep an eye on it!

0 · Reply

Bulltrader988 Aug. 15 at 6:22 PM

$ACXP 👃👀

1 · Reply

knonaogn Aug. 15 at 6:07 PM

$ACXP This stock preparation for the rise I advise starting investing here $1,000

0 · Reply

knonaogn Aug. 15 at 6:00 PM

$ACXP This stock, if successful It doesn't stop at $100.

1 · Reply

Bonso99 Aug. 15 at 5:54 PM

$ACXP getting geared up🫡🫡🫡🫡 Next week is going to be epic 🚀🚀🚀🚀

2 · Reply

knonaogn Aug. 15 at 5:35 PM

$ACXP will soon explode this very good stock I advise to invest. Inside.

0 · Reply

cninc Aug. 15 at 5:08 PM

$ACXP with Armistice here you are always just a HFT pump away.

5 · Reply

Bonso99 Aug. 15 at 5:03 PM

$ACXP 🫡SOON 🚀🚀🚀🚀LFGOOO 💫💫

0 · Reply

Applesl Aug. 15 at 4:54 PM

$ACXP

0 · Reply

Bonso99 Aug. 15 at 4:38 PM

$ACXP 🫡🫡🫡Positive and significant → high probability of FDA/EMA approval → market access → large capital gain. 🚀🚀🚀💫

0 · Reply

raticals Aug. 15 at 3:35 PM

$ACXP Luci should be investigated for securities fraud for those videos with that woman.

1 · Reply

Bonso99 Aug. 15 at 1:16 PM

$ACXP🫡🫡🫡🫡🫡🫡🚀💫 https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-acurx-pharmaceuticals-acxp-biohaven-ltd-bhvn-blurbs?utm_source=webullapp.com&utm_medium=referral

0 · Reply

Bonso99 Aug. 15 at 11:00 AM

$ACXP 👇👇👇👇👇👇🚀💫

0 · Reply

Bulltrader988 Aug. 15 at 9:19 AM

$ACXP 13G filled yesterday Armistice Capital, LLC 2,917,975 shares = 8.70 % ownership 👃👀 https://www.sec.gov/Archives/edgar/data/1601086/000117266125003563/xslSCHEDULE_13G_X01/primary_doc.xml

1 · Reply

flcountryboy Aug. 15 at 1:35 AM

$ACXP fyi...

0 · Reply

flcountryboy Aug. 15 at 1:34 AM

$ACXP fyi... ACXP - Acurx Pharmaceuticals, Inc. Stock - Stock Price, Institutional Ownership, Shareholders (NasdaqCM) https://share.google/rN35yGVyxDru4bW41

0 · Reply

milesdonaldson Aug. 15 at 1:03 AM

$ACXP I’m not a paid subscriber, but according to Fintel, Sabby is all but out and Armistace is back in? Does anyone have any insight?

1 · Reply

knonaogn Aug. 14 at 4:27 PM

$ACXP Where is this going

0 · Reply

Bonso99 Aug. 14 at 3:18 PM

$ACXP Yes — "ACXP is a huge success" is an apt phrase. Success follows strong clinical results, scientific publication, regulatory progress and patents, and strategic financing. Overall, this points to Acurx being on track to achieve a breakthrough with ibezapolstat. 💪💪💪💪💫🚀🚀🚀

0 · Reply

Market Cap	8.10M
Revenue (ttm)	0.00
Net Income (ttm)	-14.10M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	51,334
Avg Vol	407,093
Day's Range	N/A - N/A
Shares Out	1.59M
Stochastic %K	60%
Beta	-1.27
Analysts	Strong Sell
Price Target	$31.00